

| IRS cut off | Sensitivity% | 95% CI | Specificity% | 95% CI | Likelihood ratio |
|-------------|--------------|------------------|--------------|------------------|------------------|
| < 0.5000 | 10.81 | 4.285% to 24.71% | 95.05 | 88.93% to 97.87% | 2.184 |
| < 1.500 | 16.22 | 7.651% to 31.14% | 90.1 | 82.73% to 94.53% | 1.638 |
| < 2.500 | 29.73 | 17.49% to 45.78% | 86.14 | 78.07% to 91.56% | 2.145 |
| < 3.500 | 45.95 | 31.04% to 61.62% | 70.3 | 60.77% to 78.33% | 1.547 |
| < 5.000 | 64.86 | 48.76% to 78.17% | 35.64 | 26.99% to 45.35% | 1.008 |
| < 7.000 | 70.27 | 54.22% to 82.51% | 25.74 | 18.22% to 35.05% | 0.9463 |
| < 8.500 | 78.38 | 62.80% to 88.61% | 16.83 | 10.78% to 25.31% | 0.9424 |
| < 10.50 | 81.08 | 65.80% to 90.52% | 12.87 | 7.679% to 20.78% | 0.9306 |

Figure S1. The receiver operating characteristic (ROC) curves for disease specific survival using cutoff score of CLDN12-immunoreactive score (IRS) ≥ 3 . CI, confidence interval.




Figure S2. The *CLDN12* mRNA expression in various cancer tissues and the *CLDN12* protein expression in normal and malignant colon tissues. (A) Expression levels of *CLDN12* mRNA in the indicated cancer tissues were analysed using TCGA database. RSEM, RNA-Seq by Expectation-Maximization. (B) Normal and cancer tissues of the colon were immunohistochemically stained with the anti-*CLDN12* pAb and the anti-*CLDN12* mAb. HE, hematoxylin-eosin. Scale bar, 100 μ m.